Business Context and Reporting Period
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders. The reporting period covers the three months ended March 31, 2026. During this period, the company completed a corporate reorganization on March 30, 2026, moving its operations from Hemab ApS (Denmark) to a newly incorporated Delaware entity. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(22.7) million | $(15.3) million |
| Operating Expenses | $23.6 million | $16.6 million |
| Research & Development | $19.5 million | $14.1 million |
| General & Administrative | $4.2 million | $2.5 million |
| Cash and Cash Equivalents (End of Period) | $49.9 million | $55.4 million |
| Marketable Securities | $113.7 million | $97.5 million |
| Total Liquidity (Cash + Securities) | $163.5 million | $152.9 million |
| Accumulated Deficit | $(204.5) million | $(133.3) million |
Note: The filing does not provide a specific debt balance; liabilities consist primarily of accounts payable, accrued expenses, and operating lease liabilities totaling $13.7 million.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $7.4 million (48%) compared to Q1 2025, driven primarily by higher operating expenses.
- R&D Expense Growth: Research and development expenses rose by $5.4 million, attributed to a $2.3 million increase in personnel-related costs and a $2.2 million increase in discovery and other costs (consultancy resources).
- G&A Expense Growth: General and administrative expenses increased by $1.7 million, driven by higher personnel costs, equity-based compensation, and professional service fees.
- Cash Flow: Net cash used in operating activities increased to $21.6 million from $13.0 million in the prior year period.
- Corporate Structure: The company transitioned from a Danish entity to a Delaware corporation, converting convertible preference shares to convertible preferred stock.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management expects to continue incurring significant operating losses for the foreseeable future. As of March 31, 2026, the company held $163.5 million in cash and marketable securities. Management believes this, combined with net proceeds of approximately $317.2 million from an Initial Public Offering (IPO) completed on May 4, 2026 (a subsequent event), will fund operations into 2029.
Key Risks and Contingencies:
- Internal Controls: The company identified material weaknesses in its internal control over financial reporting, specifically regarding the financial statement close process and information system controls.
- Clinical Development: The company is heavily dependent on the success of its lead asset, sutacimig (Phase 1/2 for Glanzmann thrombasthenia and Factor VII deficiency), and HMB-002 (Phase 1/2 for Von Willebrand Disease). Serious adverse events of thrombosis have been identified in sutacimig development.
- Capital Requirements: The company will require substantial additional funding to advance clinical trials, particularly the planned Phase 3 trial for sutacimig.
- Regulatory Uncertainty: The FDA may require a randomized controlled trial for sutacimig approval rather than the planned single-arm trial, which could increase costs and delay timelines.
Investor Verification Checklist
- Verify IPO Proceeds: Confirm the actual net proceeds received from the May 4, 2026 IPO and the updated cash balance post-IPO.
- Internal Control Remediation: Review the specific steps and timeline management has established to remediate the identified material weaknesses in internal controls.
- Clinical Trial Design: Monitor the outcome of the planned Type D meeting with the FDA regarding the Phase 3 trial design for sutacimig (single-arm vs. randomized).
- Safety Profile: Track any new data regarding thrombotic events in the development of sutacimig and HMB-002.
- Burn Rate: Assess the quarterly cash burn rate against the projected runway into 2029 to determine if additional financing will be needed sooner than anticipated.